drugset / Trial / NCT01207297

Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis

NCT01207297

Phase 1 Completed 40 enrolled Zhejiang University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

In this comparative open-label cohort study, the investigators compared the efficacy and safety of tacrolimus (TAC)and cyclophosphamide (CYC) in the treatment of diffuse proliferative and membranous lupus nephritis with severe renal disease. Treatment of lupus nephritis (LN) with cyclophosphamide is effective, but retain a certain proportion of renal function exacerbations. Tacrolimus may be a suitable substitute treatment for CYC. Methods: Forty patients with diffuse proliferative or membranous were recruited for this trial, 45% of them had lower Ccr (\<60mL/min/1.73m2), 10% had increased serum creatinine (\>180µmol/L) and 67.5% had nephritic proteinuria (\>3.5g/day). The investigators compared the efficacy and adverse effects of TAC (0.04-0.08 mg/kg/d) and prednisone for 12 months (TAC group) with pulse cyclophosphamide (750mg/m2 per month for six months) and prednisone followed by azathioprine (50mg/day)for 6 months (CYC group).

Timeline

Start
2003-03
Primary completion
2010-03
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cyclophosphamide Other / unclassified 750 mg/m2 Intravenous
Comparator Tacrolimus Small molecule Oral